Clinical Trial Detail

NCT ID NCT03330561
Title PRS-343 in HER2-Positive Solid Tumors
Recruitment Suspended
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Pieris Pharmaceuticals, Inc.
Indications

Advanced Solid Tumor

stomach cancer

esophageal cancer

urinary bladder cancer

gastroesophageal junction adenocarcinoma

Her2-receptor positive breast cancer

Therapies

PRS-343

Age Groups: adult senior

Additional content available in CKB BOOST